Inhibition of CISD1 Attenuates Cisplatin-Induced Hearing Loss in Mice via the PI3K and MAPK Pathways

The study investigated the role of CDGSH iron sulfur domain 1 (CISD1) in cisplatin-induced hearing loss. Cisplatin, a chemotherapeutic agent, can cause hearing loss in 20%-70% of patients. The researchers used MitoNEET ligand-1 (NL-1), a CISD1-specific ligand, to inhibit CISD1 in HEI-OC1 cells, cochlear explants in vitro, and adult C57 mice in vivo. They found that CISD1 expression in cochlear hair cells and HEI-OC1 cells was upregulated after exposure to cisplatin. The study suggests that inhibiting CISD1 could potentially mitigate the side effects of cisplatin chemotherapy, including hearing loss. However, further research is needed to confirm these findings and explore the underlying mechanisms.